Sibutramine Use Banned in China: Severe Cardiovascular Risks Outweigh Benefits

December 6, 2023

Recently, the National Medical Products Administration announced that based on the comprehensive monitoring and evaluation results, the use of sibutramine may increase the risk of severe cardiovascular diseases. The risks of using sibutramine for weight loss outweigh the benefits. Therefore, the production, sale, and use of sibutramine formulations and raw materials will be discontinued in China, and the marketed drugs will be recalled and destroyed by the manufacturers. It is reported that the products affected by this ban include Qumei, Aoquqing, Kexiu, Saisimei, Quting, Puxiu, Tingli, Aolina, Qujing, Xinfenmeilin, Xiqing, Shenzhihua, Hengyun, Miaole, Nuomeiting, and many other weight loss drug brands.

The National Medical Products Administration advises that whether it is for the treatment of obesity or for those hoping to achieve body shaping by reducing weight, it is recommended to adhere to a scientific lifestyle for the long term in order to maintain weight and reduce rebound. For patients currently using sibutramine, it is suggested to consult their doctors promptly and discuss alternative medications.

Share

Everyone Is Watching

icon

Hot Picks